Literature DB >> 31529254

Noninvasive prediction of HCC with progenitor phenotype based on gadoxetic acid-enhanced MRI.

Jie Chen1, Zhenru Wu2, Chunchao Xia3, Hanyu Jiang1, Xijiao Liu3, Ting Duan3, Likun Cao1, Zheng Ye1, Zhen Zhang1, Ling Ma4, Bin Song5, Yujun Shi6.   

Abstract

OBJECTIVES: To explore the noninvasive prediction of hepatocellular carcinoma (HCC) with progenitor phenotype based on gadoxetic acid-enhanced magnetic resonance imaging (MRI).
METHODS: This retrospective study included 115 surgery-proven HCCs with preoperative gadoxetic acid-enhanced MRI from August 2015 to September 2018. Image features were reviewed. Quantitative image analysis was performed using histogram analysis. HCC with progenitor phenotype was defined as positive for either cytokeratin 19 (CK19) or epithelial cell adhesion molecule (EpCAM) expression. Statistically significant variables for identifying HCCs with progenitor phenotype were determined at multivariate analyses. ROC analyses were used to determined cutoff values and the diagnostic performance of significant variables and combinations. Prediction nomogram was constructed based on multivariate analysis.
RESULTS: At multivariate regression analyses, AFP ≥ 155.25 ng/mL (p < 0.001), skewness on T2WI ≤ 1.10 (p = 0.024), uniformity on pre-T1WI ≤ 0.91 (p = 0.024), irregular tumor margin (p = 0.006), targetoid appearance (p = 0.001), and the absence of mosaic architecture (p = 0.014) were significant predictors of HCCs expressing progenitor cell markers. Combing any three of those significant variables, it provides a diagnostic accuracy of 0.86 (95% CI 0.78-0.92) with sensitivity of 0.97 (95% CI 0.86-1.00), and specificity of 0.74 (95% CI 0.63-0.83). The C-index of the regression coefficient-based nomogram was 0.94 (95% CI 0.91-0.98).
CONCLUSIONS: Noninvasive prediction of HCCs with progenitor phenotype can be achieved with high accuracy by integrated interpretation of biochemical and radiological information, representing a handy tool for precise patient management and the prediction of prognosis. KEY POINTS: • Qualitative image features of irregular tumor margin, targetoid appearance, and the absence of mosaic architecture are significant predictors of hepatocellular carcinoma with progenitor phenotype. • Quantitative analyses using whole-lesion histogram analysis provides additional information for the prediction of hepatocellular carcinoma with progenitor phenotype. • Noninvasive prediction of hepatocellular carcinoma with progenitor phenotype can be achieved with high accuracy by integrated interpretation of clinical information and qualitative and quantitative imaging analyses.

Entities:  

Keywords:  Cytokeratin 19; Epithelial cell adhesion molecule; Hepatocellular carcinoma; Magnetic resonance imaging; Nomogram

Mesh:

Substances:

Year:  2019        PMID: 31529254     DOI: 10.1007/s00330-019-06414-2

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  27 in total

1.  Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications.

Authors:  Nazario Portolani; Arianna Coniglio; Sara Ghidoni; Mara Giovanelli; Anna Benetti; Guido Alberto Massimo Tiberio; Stefano Maria Giulini
Journal:  Ann Surg       Date:  2006-02       Impact factor: 12.969

2.  Whole-tumor MRI histogram analyses of hepatocellular carcinoma: Correlations with Ki-67 labeling index.

Authors:  Xin-Xing Hu; Zhao-Xia Yang; He-Yue Liang; Ying Ding; Robert Grimm; Cai-Xia Fu; Hui Liu; Xu Yan; Yuan Ji; Meng-Su Zeng; Sheng-Xiang Rao
Journal:  J Magn Reson Imaging       Date:  2016-11-10       Impact factor: 4.813

3.  MR features based on LI-RADS identify cytokeratin 19 status of hepatocellular carcinomas.

Authors:  Xin-Xing Hu; Wen-Tao Wang; Li Yang; Zhao-Xia Yang; He-Yue Liang; Ying Ding; Yuan Ji; Meng-Su Zeng; Sheng-Xiang Rao
Journal:  Eur J Radiol       Date:  2019-01-31       Impact factor: 3.528

Review 4.  Mosaic architecture of hepatocellular carcinoma.

Authors:  Roberto Cannella; Alessandro Furlan
Journal:  Abdom Radiol (NY)       Date:  2018-07

5.  Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.

Authors:  Julien Calderaro; Gabrielle Couchy; Sandrine Imbeaud; Giuliana Amaddeo; Eric Letouzé; Jean-Frédéric Blanc; Christophe Laurent; Yacine Hajji; Daniel Azoulay; Paulette Bioulac-Sage; Jean-Charles Nault; Jessica Zucman-Rossi
Journal:  J Hepatol       Date:  2017-05-19       Impact factor: 25.083

Review 6.  Multistep human hepatocarcinogenesis: correlation of imaging with pathology.

Authors:  Masatoshi Kudo
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

7.  Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.

Authors:  Hiroshi Imamura; Yutaka Matsuyama; Eiji Tanaka; Takao Ohkubo; Kiyoshi Hasegawa; Shinichi Miyagawa; Yasuhiko Sugawara; Masami Minagawa; Tadatoshi Takayama; Seiji Kawasaki; Masatoshi Makuuchi
Journal:  J Hepatol       Date:  2003-02       Impact factor: 25.083

8.  Sex difference in recurrence and survival after liver resection for hepatocellular carcinoma: A multicenter study.

Authors:  Han Zhang; Jun Han; Hao Xing; Zhen-Li Li; Myron E Schwartz; Ya-Hao Zhou; Ting-Hao Chen; Hong Wang; Wei-Min Gu; Wan Yee Lau; Han Wu; Meng-Chao Wu; Feng Shen; Tian Yang
Journal:  Surgery       Date:  2018-10-15       Impact factor: 3.982

9.  Poor outcome of hepatocellular carcinoma with stemness marker under hypoxia: resistance to transarterial chemoembolization.

Authors:  Hyungjin Rhee; Ji Hae Nahm; Haeryoung Kim; Gi Hong Choi; Jeong Eun Yoo; Hye Sun Lee; Myoung Ju Koh; Young Nyun Park
Journal:  Mod Pathol       Date:  2016-06-17       Impact factor: 7.842

10.  Association Between Expression of Cancer Stem Cell Markers and Poor Differentiation of Hepatocellular Carcinoma: A Meta-Analysis (PRISMA).

Authors:  Rui Liu; Yuan Shen; Kejun Nan; Baibing Mi; Tao Wu; Jinyue Guo; Miaojing Li; Yi Lv; Hui Guo
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.889

View more
  6 in total

Review 1.  Up-to-Date Role of CT/MRI LI-RADS in Hepatocellular Carcinoma.

Authors:  Guilherme Moura Cunha; Victoria Chernyak; Kathryn J Fowler; Claude B Sirlin
Journal:  J Hepatocell Carcinoma       Date:  2021-05-31

2.  Preoperative radiomics model using gadobenate dimeglumine-enhanced magnetic resonance imaging for predicting β-catenin mutation in patients with hepatocellular carcinoma: A retrospective study.

Authors:  Fengxia Zeng; Hui Dai; Xu Li; Le Guo; Ningyang Jia; Jun Yang; Danping Huang; Hui Zeng; Weiguo Chen; Ling Zhang; Genggeng Qin
Journal:  Front Oncol       Date:  2022-09-16       Impact factor: 5.738

Review 3.  Gadoxetate-Enhanced MRI as a Diagnostic Tool in the Management of Hepatocellular Carcinoma: Report from a 2020 Asia-Pacific Multidisciplinary Expert Meeting.

Authors:  Cher Heng Tan; Shu-Cheng Chou; Nakarin Inmutto; Ke Ma; RuoFan Sheng; YingHong Shi; Zhongguo Zhou; Akira Yamada; Ryosuke Tateishi
Journal:  Korean J Radiol       Date:  2022-05-09       Impact factor: 7.109

4.  Prognostic role of multiparameter MRI and radiomics in progression of advanced unresectable hepatocellular carcinoma following combined transcatheter arterial chemoembolization and lenvatinib therapy.

Authors:  Junpeng Luo; Zhimei Huang; Murong Wang; Tian Li; Jinhua Huang
Journal:  BMC Gastroenterol       Date:  2022-03-08       Impact factor: 3.067

5.  Preoperative prediction of hepatocellular carcinoma with highly aggressive characteristics using quantitative parameters derived from hepatobiliary phase MR images.

Authors:  Zheng Ye; Likun Cao; Yi Wei; Jie Chen; Zhen Zhang; Shan Yao; Ting Duan; Bin Song
Journal:  Ann Transl Med       Date:  2020-02

6.  Preoperative Prediction of Cytokeratin 19 Expression for Hepatocellular Carcinoma with Deep Learning Radiomics Based on Gadoxetic Acid-Enhanced Magnetic Resonance Imaging.

Authors:  Yuying Chen; Jia Chen; Yu Zhang; Zhi Lin; Meng Wang; Lifei Huang; Mengqi Huang; Mimi Tang; Xiaoqi Zhou; Zhenpeng Peng; Bingsheng Huang; Shi-Ting Feng
Journal:  J Hepatocell Carcinoma       Date:  2021-07-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.